Bibliography
- Massberg S, Von Andrian UH. Fingolimod and sphringosine-1-phosphate – modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-91
- Kappos L, Antel J, Comi G, Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
- O'Connor P, Comi G, Montalban X, Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9
- Comi G, O'Connor P, Montalban X, Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3 year results. Mult Scler 2010;16:197-207
- Kappos L, Radue E-M, O'Connor P, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
- Cohen JA, Barkhof F, Comi G, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
- Fingolimod. Available from: http://clinicaltrials.gov/ct2/results?term=fingolimod&pg=1. [Last accessed 12 February 2010]
- Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009;10:291-309
- Durelli L, Verdum E, Barbero P, Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
- O'Connor P, Filippi M, Arnason B, 250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
- Giovannoni G, Comi G, Cook S, A placebo-controlled trial of oral cladribine for relasing multiple sclerosis. N Engl J Med 2010;362:416-26